

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM531576

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
WHITE OAK GLOBAL ADVISORS, LLC, AS AGENT		07/11/2019	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	AQUESTIVE THERAPEUTICS, INC.		
<b>Also Known As:</b>	F/K/A MONOSOL RX, LLC		
<b>Street Address:</b>	30 Technology Drive		
<b>City:</b>	Warren		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	07059		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3336176	MONOSOL RX	
<b>Serial Number:</b>	76577939	PHARMFILM	
<b>Serial Number:</b>	78618508	RX	
<b>Registration Number:</b>	3349534		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2126983599		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2126983500		
<b>Email:</b>	patents@dechert.com		
<b>Correspondent Name:</b>	DECHERT LLP		
<b>Address Line 1:</b>	THREE BRYANT PARK		
<b>Address Line 2:</b>	1095 AVENUE OF THE AMERICAS		
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10036		
<b>NAME OF SUBMITTER:</b>	THOMAS A. RAYSKI		
<b>SIGNATURE:</b>	/Thomas A. Rayski/		
<b>DATE SIGNED:</b>	07/12/2019		
<b>Total Attachments: 4</b>			

CH \$115.00 3336176

source=2019-07-12\_Aquestive\_fka\_MonoSol\_TM\_Release#page1.tif  
source=2019-07-12\_Aquestive\_fka\_MonoSol\_TM\_Release#page2.tif  
source=2019-07-12\_Aquestive\_fka\_MonoSol\_TM\_Release#page3.tif  
source=2019-07-12\_Aquestive\_fka\_MonoSol\_TM\_Release#page4.tif

**TERMINATION AND RELEASE OF  
TRADEMARK SECURITY AGREEMENT**

**THIS TERMINATION AND RELEASE OF TRADEMARK SECURITY AGREEMENT** (this "Agreement"), dated as of July 11, 2019, is between Aquestive Therapeutics, Inc. (f/k/a MonoSol Rx, LLC), a Delaware limited liability company (the "Grantor"), and White Oak Global Advisors, LLC, a Delaware limited liability company, as agent for the benefit of the Secured Creditors (as hereinafter defined) ("Agent").

WHEREAS, Grantor has previously entered into that certain Loan and Security Agreement, dated as of April 1, 2008 (as amended, supplemented and/or otherwise modified from time to time, the "Loan Agreement"), among Grantor, the entities which from time to time are parties thereto as Guarantors, the entities which from time to time are parties thereto as Lenders, and Agent, pursuant to which Lenders have agreed, subject to certain terms and conditions, to extend various financial accommodations to Grantor (Agent and Lenders are sometimes hereinafter referred to collectively as "Secured Creditors");

WHEREAS, in order to partially secure the Grantor's obligations to the Agent under the Loan Agreement, the Grantor executed and delivered in favor of the Agent that certain Trademark Security Agreement, dated as of April 1, 2008 (the "Trademark Security Agreement"), pursuant to which the Grantor pledged and granted to the Agent a security interest and lien in the Trademark Collateral, which includes, without limitation, the trademarks, and trademark applications listed on Schedule A hereof, to secure its payment obligations under the Loan Agreement; and

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office (the "USPTO") on April 11, 2008 at Reel 003759, Frame 0353; and

WHEREAS, all capitalized terms used herein not otherwise defined shall have the meanings ascribed to such terms in the Loan Agreement.

NOW, THEREFORE, in consideration of the foregoing premises, the mutual covenants and agreements of the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. Termination of Collateral Assignment. The Trademark Security Agreement is hereby terminated and deemed of no further force or effect and that each party thereto shall have no further obligation thereunder.

2. Release of Security Interest. The Agent hereby terminates, cancels, discharges and releases any and all liens and security interests in and to the Trademark Collateral, including, without limitation, the trademarks, and trademark applications listed on Schedule A hereof. The Agent hereby reassigns, grants and conveys to the Grantor, without any representation, recourse or undertaking by the Agent, all of the Agent's right, title and interest in and to the Trademark Collateral.

3. Recording with USPTO. The Agent hereby authorizes the Grantor to file and record this Agreement with the USPTO.

4. Representations and Warranties. Each party hereto represents and warrants to the other party that: (i) it has all requisite power and authority to enter into this Agreement; (ii) the execution, delivery and performance of this Agreement has been fully authorized by all necessary action on its part and does not violate any provision of any agreement, charter, order, judgment or law to which it is a party or by which it or its properties are bound; and (iii) this Agreement constitutes the legal, valid and binding obligation of such party enforceable against it in accordance with its terms, except as may be limited by bankruptcy, insolvency and similar laws affecting the rights of creditors generally and by general principles of equity.

5. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantor, and the Grantor's successors, permitted assigns or other legal representatives, all such cooperation and assistance (including, but not limited to, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor to effectuate the purposes of this Agreement.

6. Governing Law. This Agreement shall be in accordance with and governed by the laws of the State of New York without regard to principles of conflicts of law (other than New York General Obligations Law 5-1401 and 5-1402).


7. Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

8. Counterparts. This Agreement may be executed in any number of counterparts each of which when so executed and delivered shall be deemed an original, but all of which together shall constitute one and the same instrument.


*[Signature pages follow]*

IN WITNESS WHEREOF, the undersigned have duly executed this Agreement as of the date first above written.

**AQUESTIVE THERAPEUTICS, INC.**

By:   
Name: Robert C. Agard  
Title: Vice President, Finance

**WHITE OAK GLOBAL ADVISORS, LLC**

By:   
Name: David B. Hackett  
Title: Co-President

Termination and Release of Trademark Security Agreement

**SCHEDULE A  
TRADEMARKS**

<b>Trademark</b>	<b>Country</b>	<b>Registration/Serial Number</b>
MONOSOL RX	United States	3,336,176
PHARMFILM	United States	76/577,939
RX & Design	United States	78/618,508
TEAR DROP Logo	United States	3,349,534
MISCELLANEOUS DESIGN (TEAR DROP LOGO)	Mexico	916675
MONOSOL RX	Mexico	916674
MISCELLANEOUS DESIGN (TEAR DROP LOGO)	Japan	4945791
MONOSOL RX & Design	Japan	5043346
MISCELLANEOUS DESIGN (TEAR DROP LOGO)	European Community	4720637
MISCELLANEOUS DESIGN (TEAR DROP LOGO)	European Community	4042834
MONOSOL RX	European Community	4720694
MONOSOL RX	Canada	1278012
TEAR DROP Logo	Canada	1278011
MISCELLANEOUS DESIGN (TEAR DROP LOGO)	Australia	1082829
MONOSOL RX	Australia	1082831